TP53 and colorectal cancer: ,7 For instance, TP53 mutants occur in approximately 50% of all samples, and TP53 mutants in colorectal cancer are associated with nutlin-3a (MDM2 inhibitor) resistance (Figure S1C, S2F, and S2G).14